Back

Baseline characteristics and outcomes of extended oral anticoagulant treatment in patients with venous thrombosis: a retrospective cohort study in France

28 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus Anticoagulants ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Rupesh Subash

Pfizer Ltd, Surrey (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting
Doctor A. Cohen (London, GB)
Abstract Slides Video
Presentation thumbnail
The effect of DOAC-Stop on lupus anticoagulant testing in patients with pulmonary embolism receiving direct oral anticoagulants
Professor A. Undas (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
Anticoagulant therapy beyond primary treatment among active cancer and non-cancer patients with venous thromboembolism in the United States
Doctor A. Cohen (London, GB)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and outcomes of super-low-dose edoxaban of 15 mg in patients with acute venous thromboembolism: insight from the COMMAND VTE Registry-2
Doctor K. Kaneda (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Predicting thrombus outcome during anticoagulation for left ventricular thrombus
Doctor Q. Yang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

The Event

Event poster

ESC Congress 2023

28 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
thumbnail
Congress Presentation
Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting
thumbnail
Congress Presentation
Anticoagulant therapy beyond primary treatment among active cancer and non-cancer patients with venous thromboembolism in the United States

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources